{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:13:37Z","timestamp":1768796017189,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Human Capacities of Hungary"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pharep.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T03:56:34Z","timestamp":1517543794000},"page":"650-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of central RVD-hemopressin(\u03b1) administration on anxiety, feeding behavior and hypothalamic neuromodulators in the rat"],"prefix":"10.1007","volume":"70","author":[{"given":"Lucia","family":"Recinella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiavaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Macedonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzurra","family":"Stefanucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilisa Pia","family":"Dimmito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szabolcs","family":"Dvor\u00e1csk\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"T\u00f6mb\u00f6ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2018.01.010_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-319-20825-1_9","article-title":"Endocannabinoids and mental disorders","volume":"231","author":"Rubino","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0010","first-page":"165","article-title":"Antidepressant\u2013like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors","volume":"61","author":"Rutkowska","year":"2004","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.pharep.2018.01.010_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0269881110376688","article-title":"Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems","volume":"25","author":"Zarrindast","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0020","first-page":"217","article-title":"Activation of endocannabinoid transmission induces antidepressant-like effects in rats","volume":"59","author":"Adamczyk","year":"2008","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/ijo.2015.179","article-title":"New insights on the role of the endocannabinoid system in the regulation of energy balance","volume":"40","author":"Gatta-Cherifi","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharep.2018.01.010_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biopsych.2004.10.032","article-title":"Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents","volume":"57","author":"Griebel","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharep.2018.01.010_bib0035","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"issue":"169","key":"10.1016\/j.pharep.2018.01.010_bib0040","first-page":"4360","article-title":"A meta-analysis of the efficacy and safety of the anti-obesity agent rimonabant","volume":"10","author":"Christensen","year":"2007","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.pharep.2018.01.010_bib0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.pharep.2018.01.010_bib0050","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1523\/JNEUROSCI.5455-09.2010","article-title":"The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice","volume":"30","author":"Dodd","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharep.2018.01.010_bib0055","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.pharep.2017.05.015","article-title":"Anorexigenic effects induced by RVD-hemopressin(\u03b1) administration","volume":"69","author":"Ferrante","year":"2017","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2018.01.010_bib0060","doi-asserted-by":"crossref","first-page":"20588","DOI":"10.1073\/pnas.0706980105","article-title":"Hemopressin is an inverse agonist of CB1 cannabinoid receptors","volume":"104","author":"Heimann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharep.2018.01.010_bib0065","doi-asserted-by":"crossref","first-page":"36944","DOI":"10.1074\/jbc.M112.382481","article-title":"Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors","volume":"287","author":"Bauer","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharep.2018.01.010_bib0070","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.113.209866","article-title":"Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(\u03b1)], an N-terminally extended hemopressin peptide","volume":"348","author":"Han","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2018.01.010_bib0075","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1038\/s41598-017-09808-8","article-title":"Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage","volume":"7","author":"Petrucci","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharep.2018.01.010_bib0080","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.pharep.2017.06.010","article-title":"Emotional disorders induced by Hemopressin and RVD-hemopressin(\u03b1) administration in rats","volume":"69","author":"Leone","year":"2017","journal-title":"Pharmacol Rep"},{"issue":"20","key":"10.1016\/j.pharep.2018.01.010_bib0085","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 recepto","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0090","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors","volume":"8","author":"Mart\u00ednez-Pinilla","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0100","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharep.2018.01.010_bib0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2018.01.010_bib0110","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pbb.2011.01.007","article-title":"Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists","volume":"98","author":"Scopinho","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2018.01.010_bib0120","first-page":"181","article-title":"Interaction between orexin-A and cannabinoid system in the lateral hypothalamus of rats and effects of subchronic intraperitoneal administration of cannabinoid receptor inverse agonist on food intake and the nutritive utilization of protein","volume":"66","author":"Merroun","year":"2015","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0125","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fnins.2013.00256","article-title":"Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far","volume":"7","author":"Flores","year":"2013","journal-title":"Front Neurosci"},{"key":"10.1016\/j.pharep.2018.01.010_bib0130","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-017-01782-z","article-title":"Orexin modulates behavioral fear expression through the locus coeruleus","volume":"8","author":"Soya","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharep.2018.01.010_bib0135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/0929866523666161007152435","article-title":"Hemopressin peptides as modulators of the endocannabinoid system and their potential applications as therapeutic tools","volume":"23","author":"Macedonio","year":"2016","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.pharep.2018.01.010_bib0140","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.peptides.2011.08.003","article-title":"Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat","volume":"32","author":"Brunetti","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.pharep.2018.01.010_bib0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.peptides.2013.03.019","article-title":"Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus","volume":"44","author":"Brunetti","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.pharep.2018.01.010_bib0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.peptides.2013.11.007","article-title":"Peripheral chemerin administration modulates hypothalamic control of feeding","volume":"51","author":"Brunetti","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.pharep.2018.01.010_bib0155","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1016\/j.bmc.2015.07.066","article-title":"Exploring new probenecid-based carbonic anhydrase inhibitors: synthesis, biological evaluation and docking studies","volume":"23","author":"Mollica","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharep.2018.01.010_bib0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/157340720903140119151919","article-title":"The evolution of peptide synthesis: from early days to small molecular machines","volume":"9","author":"Mollica","year":"2013","journal-title":"Curr Bioact Compd"},{"key":"10.1016\/j.pharep.2018.01.010_bib0165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cbdd.12479","article-title":"Design, synthesis and biological evaluation of two opioid agonist and cav2.2 blocker multitarget ligands","volume":"86","author":"Mollica","year":"2015","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.pharep.2018.01.010_bib0170","first-page":"797","article-title":"Effects of central fibroblast growth factor 21 and irisin in anxiety-like behavior","volume":"31","author":"Chiavaroli","year":"2017","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.pharep.2018.01.010_bib0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ghir.2014.12.007","article-title":"Increased locomotor and thermogenic activity in mice with targeted ablation of the GHRH gene","volume":"25","author":"Leone","year":"2015","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0180","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ghir.2014.06.004","article-title":"Behavioural phenotyping of male growth hormone-releasing hormone (GHRH) knockout mice","volume":"24","author":"Leone","year":"2014","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.peptides.2013.07.021","article-title":"Orexigenic effects of endomorphin-2 (EM-2) related to decreased CRH gene expression and increased dopamine and norepinephrine activity in the hypothalamus","volume":"48","author":"Brunetti","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.pharep.2018.01.010_bib0190","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.pharep.2014.06.014","article-title":"Hypotensive effects of omentin-1 related to increased adiponectin and decreased interleukin-6 in intra-thoracic pericardial adipose tissue","volume":"66","author":"Brunetti","year":"2014","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2018.01.010_bib0195","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.pharep.2018.01.010_bib0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.pharep.2018.01.010_bib0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/17460441.2014.966680","article-title":"Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease","volume":"10","author":"Wyrofsky","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.pharep.2018.01.010_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2007.01.023","article-title":"What's wrong with my mouse model?: advances and strategies in animal modeling of anxiety and depression","volume":"179","author":"Kalueff","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature14260","article-title":"Hypothalamic POMC neurons promote cannabinoid-induced feeding","volume":"519","author":"Buck","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharep.2018.01.010_bib0220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pbb.2006.12.020","article-title":"Repeated cannabinoid administration increases indices of noradrenergic activity in rats","volume":"86","author":"Page","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2018.01.010_bib0225","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/bph.13440","article-title":"Involvement of the orexin\/hypocretin system in the pharmacological effects induced by \u0394(9)\u2013tetrahydrocannabinol","volume":"173","author":"Flores","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.010_bib0230","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"57","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pharep.2018.01.010_bib0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0031-9384(00)00341-3","article-title":"Effects of leptin and orexin-A on food intake and feeding related hypothalamic neurons","volume":"71","author":"Shiraishi","year":"2000","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharep.2018.01.010_bib0240","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin-A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharep.2018.01.010_bib0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(00)02555-5","article-title":"Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system","volume":"873","author":"Nakamura","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2009.09.019","article-title":"Hypocretin\/Orexin in arousal and stress","volume":"1314","author":"Berridge","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0255","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5665\/sleep.2232","article-title":"The dual orexin-A receptor antagonist almorexant induces sleep and decreases orexin-A-induced locomotion by blocking orexin-A 2 receptors","volume":"35","author":"Mang","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.pharep.2018.01.010_bib0260","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0166-2236(00)02002-6","article-title":"The sleep switch: hypothalamic control of sleep and wakefulness","volume":"24","author":"Saper","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharep.2018.01.010_bib0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-0173(03)00143-7","article-title":"The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes","volume":"42","author":"Berridge","year":"2003","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.pharep.2018.01.010_bib0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0926-6410(95)90007-1","article-title":"Novelty seeking behavior in the rat is dependent upon the integrity of the noradrenergic system","volume":"2","author":"Sara","year":"1995","journal-title":"Brain Res Cogn Brain Res"},{"key":"10.1016\/j.pharep.2018.01.010_bib0275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.158.3800.515","article-title":"Localization of the adrenergic feeding system in the rat diencephalon","volume":"158","author":"Booth","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.pharep.2018.01.010_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/S0899-9007(00)00415-9","article-title":"Norepinephrine and the control of food intake","volume":"16","author":"Wellman","year":"2000","journal-title":"Nutrition"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017308010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017308010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:31Z","timestamp":1752611851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.01.010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1734114017308010"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.01.010","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of central RVD-hemopressin(\u03b1) administration on anxiety, feeding behavior and hypothalamic neuromodulators in the rat","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}